logo
logo

Atia Vision Closes Second Tranche Of $20M In Series D Financing

Atia Vision Closes Second Tranche Of $20M In Series D Financing

05/19/20, 11:08 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgcampbell
Money raised
$20 million
Round Type
series d
 Atia Vision, Inc., a Shifamed portfolio company committed to improving patient outcomes through the development of a modular presbyopia-correcting accommodating intraocular lens, today announced the closing of its second tranche of a Series D $20M financing. Led by Cormorant Asset Management, with participation by The Capital Partnership (TCP), AMED Ventures and Shangbay Capital, the financing will be used to continue early clinical experience treating cataract patients and support expansion of Atia Vision's facility.

Company Info

Company
Atia Vision, Inc.
Location
campbell, kentucky, united states
Additional Info
Founded by serial entrepreneur Amr Salahieh, Shifamed LLC is a highly specialized medical innovation hub focused on developing solutions that accelerate time to market, reduce risk, increase impact, and forge a path toward a world where patients are able to lead longer, healthier lives. To learn more about Shifamed, please visit www.shifamed.com. MEDIA CONTACT: Katie ArnoldSPRIG Consulting LLC+1 (408) 805-0520 katie@sprigconsulting.com *The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, vision and interventional solutions businesses within Johnson & Johnson's Medical Devices segment. Biosense Webster, Johnson & Johnson, and NuVision are trademarks of Johnson & Johnson. SOURCE Shifamed LLC

Related People